Australia markets closed

Novozymes A/S (0Q4U.IL)

IOB - IOB Delayed price. Currency in DKK
Add to watchlist
428.20+0.30 (+0.07%)
At close: 05:48PM GMT
Full screen
Previous close427.90
Open420.80
Bid418.90 x 0
Ask437.00 x 0
Day's range419.70 - 429.80
52-week range353.40 - 546.00
Volume36,028
Avg. volume82,941
Market cap122.117B
Beta (5Y monthly)0.39
PE ratio (TTM)34.96
EPS (TTM)12.25
Earnings dateN/A
Forward dividend & yield5.50 (1.33%)
Ex-dividend date17 Mar 2022
1y target est411.63
  • GlobeNewswire

    As one of the first companies in the world, Novozymes has had its net-zero target validated by the Science Based Targets initiative

    Novozymes has renewed its climate targets and by 2030 will reduce its absolute CO2 emissions across its operation by 75% and reduce its absolute CO2 emissions from its supply chain by 35%. By 2050, Novozymes will reach net-zero. COPENHAGEN, Denmark – November 10, 2022. Novozymes’ first science-based targets were approved in 2019. Today Novozymes has new, SBTi approved near and long-term science-based emission reduction targets and is one of the first companies in the world to have committed to S

  • GlobeNewswire

    Novozymes and LinusBio announce collaboration to accelerate scientific discovery in Biohealth

    COPENHAGEN, Denmark – November 10, 2022. Novozymes, the world leader in biological solutions, and LinusBio (Linus Biotechnology Inc.), a leader in precision exposome sequencing, today announced the companies are forming a collaboration to test a new, non-invasive technology in a clinical trial. The project will apply LinusBio’s environmental biodynamics platform, enabling detailed temporal mapping of harmful compound exposure, to a clinical trial of probiotics sponsored by Novozymes’ human healt

  • GlobeNewswire

    Novozymes confirms upgraded guidance by strong start to Q4

    Novozymes delivered 9% organic sales growth in the first nine months of 2022 and 6% organic sales growth in the third quarter. As announced on October 7, the full-year organic sales growth outlook was raised from 6-8 % to now 8-9 % following a strong performance in the first nine months of the year, and expectedly, continued strong Q4 momentum. COPENHAGEN, Denmark – November 3, 2022. In the first nine months of the 2022 financial year, Novozymes delivers 9% organic sales growth, an EBIT-margin o